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 Introduction 
 This chapter discusses standards, an elusive term and concept. For the 
African pharmaceutical sector especially, the term is used by the manu-
facturing sector, regulators, technical experts, procurement agencies, 
health system actors and policy makers to mean different things. There 
is a dearth of systematic studies that address what standards are, their 
classification and the logic behind their set-up and operation, and this 
has contributed to a huge asymmetry in understanding. The socio-
economic, technical and political issues and how they have an impact 
on local production and industry development, including their effects 
on access to markets, have also not been systematically explored. 
 A common understanding of standards, their classifications and devel-
opment, is important as the continent implements the African Union’s 
Pharmaceutical Manufacturing Plan of Action (see also Chapter 15). 
Even more important is the need for African technical experts, regula-
tors and policy makers to realize that standards and their development 
in the pharmaceutical sector is a process under their control. They can 
drive agenda setting and design realistic and context-sensitive road maps 
which align local industry development without compromising public 
health safety. The ability of policy makers to take a critical approach to 
the meaning and use of standards in the African pharmaceutical sector 
is an important enabler for designing road maps. 
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 In this chapter we set up some of the issues that need further debate. 
We deconstruct standards and classify them into two groups; technically 
based standards and organizational or institutionally based standards. 
Technically based standards cover product, process, plant and envi-
ronmental aspects. Organizational or institutionally based standards 
are those which are important for creating market confidence in firms’ 
output through assuring the credibility and legitimacy of products, 
quality, production, distribution and recall processes. This credibility 
and legitimacy arises from physical inspections of production and distri-
bution facilities, and the availability and examination of documenta-
tion and data management processes – administrative activities essential 
for endorsement, certification and accreditation. 
 We argue that this perspective helps to build an understanding of 
which types of standards are ‘mutable’ 1 – that is, judgement-based 
standards such as inspection, certification and accreditation for which 
capability building and improvement is a gradual process. By contrast, 
standards which cannot be compromised are those which deal directly 
with patient and public health safety concerns, namely quality, safety 
and efficacy of medicines. Such distinctions aid technical and policy 
people in designing and implementing appropriate interventions and 
road maps for technological capability and standards upgrading which 
do not compromise locally manufactured medicines’ quality, safety and 
efficacy. These distinctions also help in crafting responsive, context-
sensitive standards and compliance development processes that do not 
impose unnecessarily high costs or regulatory barriers on existing local 
industry. Our discussion of standards is informed by extensive literature 
searches, fieldwork in India, Kenya, Zimbabwe and South Africa where 
we interviewed technical experts in 2014, and interaction with regula-
tory and compliance experts in the UK. 
 A brief historical perspective 
 The history of standards in the pharmaceutical industry is traceable 
to adverse events in patient safety, and one of the notable failures was 
the 1950–60s thalidomide disaster (Grabowski et al., 1978), in which 
a morning sickness pill containing thalidomide taken by pregnant 
mothers resulted in newborns with severe birth defects. The disaster 
catalysed stringent drug approval and monitoring processes, necessi-
tating the passing of the Kefauver-Harris Drug Amendments Act in 1962 
which called for proof of safety and efficacy in the approval process, 
approvals that now use animal testing and clinical trials that can take 
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up to 12 years. The logic for the development of stringent regulation 
was that there was a need for an independent government regulatory 
agency to ensure public health whose goals were not compromised by 
commercial interests of pharmaceutical companies (Abraham, 2002). All 
stages of the drug life cycle are regulated from drug discovery to release 
of the drug on the market (Harper et al., 2007). Table 12.1 summarizes 
five key stages in the life cycle of a pharmaceutical drug, and the regula-
tory requirements or standards pertinent for each stage. 
 For drug discovery, the key guideline is good laboratory practice 
(GLP), and for phase 1 to 3 clinical trials the guideline is good clinical 
practice (GCP). When the drug moves to the production phase, good 
manufacturing practice (GMP) becomes the guiding regulatory require-
ment, followed by good distribution practice guideline for distribution 
covering traceability of medicines (systematic identification of products) 
to aid in organized defective product recall from the market. For post-
market surveillance, pharmacovigilance is the regulatory requirement. 
In addition, there is a wide range of other regulatory requirements at 
 Table 12.1  Drug life cycle stages and regulatory requirements 
 Drug life cycle stage  Regulatory requirements/Guidelines 
Drug discovery Good laboratory practice (GLP): these guidelines 
focus on toxicological safety and protection of 
the test subject
Clinical trials (phases 1, 2, 3) Good clinical practice (GCP): these guidelines 
consider product efficacy and safety evaluation, 
as well as individual protection and safety 
during testing
Manufacturing Good manufacturing practice (GMP): these 
guidelines are concerned with assuring a 
manufactured product’s quality, safety and 
efficacy, for both the product and the patient. 
The process aims to build in quality and ensure 
quality standards.
Distribution Good distribution practice: these guidelines deal 
with storage, transportation and traceability for 
product recall.
Post-market surveillance Pharmacovigilance: Sometimes called phase 4, 
this is monitoring of the product after market 
authorisation to check for any adverse events or 
product failure in all respects.
 Source : Adapted from Harper et al. (2007) and Muller et al. (1996). 
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supranational and national levels, inspired by public health concerns 
and safeguards against drug disasters, to address trade and market entry 
obligations (Immel, 2001). 
 The situation is less complex and expensive for generic medicines, 
which are modelled on branded drugs, since proof of safety and efficacy 
has already been demonstrated for the branded drug. The generic drug 
producer needs at the minimum to demonstrate the equivalence of the 
drug for approval and it does not go through rigorous clinical trials. The 
bulk of medicines produced in Africa are generics, and consequently the 
standards that we will discuss in this chapter focus on generics manufac-
ture. We do not cover standards in drug discovery and clinical trials. 
 While the first set of GMP guidelines for manufacturing, processing, 
packing or holding finished pharmaceuticals was introduced by the US 
Food and Drug Administration (FDA) in 1963 (Immel, 2000), the WHO 
has spearheaded the standards-setting process since the late 1960s, 
coming up with several amendments and extensions to the guidelines. 
In this chapter we focus on good manufacturing practice (GMP), defined 
by the WHO (2004) as the part of quality assurance that ensures that 
products are consistently produced and controlled to the quality stand-
ards appropriate to their intended use and as required by market author-
ization. Many countries, including India, Kenya and South Africa, have 
developed their own GMP guidelines based on the WHO guidelines. The 
WHO is thus a global technical agency responsible for setting stand-
ards and normative guidance and for establishing best practice, all of 
which are implemented through national drug regulatory authorities 
(DRAs) and other relevant institutions. There is criticism, however, that 
the WHO sets standards for all its member states regardless of the level 
of development. There is also some questioning of the way in which 
the WHO has shifted from a solely advisory body (technical assistance 
included) towards acting as a regulatory body after it began pre-qualifi-
cations of pharmaceutical products for developing countries. WHO pre-
qualification has acted as a catalyst for upgrading facilities in developing 
countries, but its stringent requirements have also been an impediment 
to market access to global donor-funded medicines purchase, in particu-
larly for HIV/AIDS, TB and anti-malarial drugs. 
 Standards, their establishment and assurance 
 A standard can be viewed broadly as a consensus between different agents 
to do certain key activities according to agreed-upon rules (Nickerson 
and Muehlen, 2006). This is a definition of standards as a process: a 
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common and agreed understanding of the rules of the game and how 
it is played, which resonates with the definition of institutions. These 
standards, therefore, operate on the back of strong institutional and 
organizational arrangements empowered to certify compliance with set 
rules through proclamations or a tightly controlled allocation of insignia 
or certification. Independent validation from a third party is critical for 
building confidence of other stakeholders who lack inside information 
or the means to gather credible information to make informed deci-
sions. Standards therefore provide consumers with a basis for making 
informed consumption decisions and manufacturers with a benchmark 
of best practice (Nadvi, 1999) and hence a competitive tool. 
 A technology standard, on the other hand, is defined as ‘a set of 
specifications to which all elements of products, processes, formats or 
procedures under its jurisdiction must conform’ (Tassey, 2000: 58). This 
form of standards has been credited with the standardization that has 
significantly reduced manufacturing costs through economies of scale 
achieved by mass-production of similar or ‘standard’ components (Katz 
and Shapiro, 1985; Farrell and Saloner, 1986). It is argued that the pres-
ence of standards reduces uncertainty by providing actors with a frame-
work that enables widespread diffusion of a technology (Rosenberg, 
1976), as well as a modular approach to the production process where 
components can be manufactured by different producers. 
 Organizational or institutionally based standards interact with tech-
nology standards through the processes of data or process interrogation 
against set norms, validation, acceptance and certification. Thus certi-
fication and/or accreditation of products or firms affirm that accepted 
best practice (norms), ‘standardized’ and imbued with accountability, 
has been used at various stages in a product’s design, development, 
manufacture, distribution and disposal. Specifically for the pharmaceu-
tical sector, inspection, validation, certification, accreditation and regu-
lation provide a system of traceability and accountability. This is done 
through detailed verification of quality-dependent procedures through 
internal and independent audits, quality training of personnel and 
constant monitoring of quality performance measures (Nadvi, 1999), as 
well as market performance and rectification in cases of failure. 
 Government departments, regulatory agencies, pharmaceutical 
companies’ industry associations and other stakeholders play key roles 
in the design, implementation and refinement of policies and stand-
ards governing the sector. The credibility of a standard setting and 
monitoring process depends on the representativeness of the political 
process, how well it exploits existing technical knowledge, matches 
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context of application, and how committed participants are to the issue 
at hand (Fischhoff, 1984). These processes inherently reflect different 
interests, power structures and the resources of different stakeholders. 
Consequently and at the heart of this discussion, low-income countries 
tend to typically be ‘standard takers’ rather than ‘standard makers’, with 
the responsibility for implementation, monitoring and enforcement of 
the standards resting with the national governments (Stephenson, 1997), 
which in many African settings are resource-constrained. It is with this 
background to technical and organizational/institutional standards that 
we argue that African technical and policy organs need to gain a confi-
dent understanding that designing and implementing a road map to 
improving standards in the pharmaceutical value chain is something 
that is and should be under their control. 
 Standards as tools for competition and pressure to improve 
 The significance of standards has grown over time and they have come to 
represent an important locus of collective strategy (Astley and Fombrun, 
1983) within which the ‘rules of the game’ are set (Jain, 2012). For many 
producers and service providers in both the global North and South, 
compliance with international standards can add a competitive edge 
and form a necessary condition to access niche markets (Nadvi, 1999). 
More recent research emphasizes that standards provide opportunities 
and incentives for low-income countries to modernize local industry and 
strengthen supply of quality products (Jaffe and Henson, 2004; World 
Bank, 2005). This growing evidence base suggests that in low-income 
countries standards can link upgrading local industrial capabilities with 
supply of medicines and hence better local health service quality and 
inclusiveness (Nadvi and Waltring, 2002). 
 It has been argued that good-quality and affordable pharmaceutical 
products, whether imported or locally produced, depend largely on 
the outcome of standards-based competition (Narayanan and Chen, 
2012). In the international trade literature, research suggests stand-
ards can be non-tariff barriers to trade (Stephenson, 1997; Wilson and 
Abiola, 2003), with regards to labour (Maskus et al., 2004; Maskus and 
Wilson, 2001) and environmental standards (Anderson, 1996; Anders 
and Caswell, 2009). These barriers emanate from inadequate provi-
sion of finance, local governance and regulatory structures. Kaplinsky 
et al. (2011) considered how standards such as hazard analysis critical 
control points (HACCP) and International Standards Organisation 
(ISO) are used as non-tariff barriers, especially for resource-constrained 
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countries. Supporting this assertion, a growing body of literature shows 
that without financial and technological support for domestic manufac-
turers, standards create significant cost and international market entry 
barriers (EC, 1997; Nadvi, 1999; Stephenson 1997). 
 International procurement practices and requirements of donors 
often enforce higher pharmaceutical quality standards than stipulated 
by national regulatory authorities. Implementation of these higher 
standards by local firms and achieving certification requires investment 
in people, equipment and changes in production organization as well as 
management practices – a costly exercise. Multiple accreditation caused 
by the need for local, regional and international certification such as 
WHO pre-qualification has direct negative bottom-line impact. One 
African firm reported during fieldwork that a WHO pre-qualification 
inspection can cost as much as US$100,000, a large financial burden 
especially if accreditation and certification is not supported by success 
with global health and international medicine supply tenders. As a result, 
some local industrialists have questioned the logic of solving national-
level institutional failure at supranational level. They argue that it is 
better to strengthen local regulatory authorities or take the harmoniza-
tion route by solving the institutional challenges at national or regional 
level. These criticisms inform our critical discussion of standards, what 
they are and how road maps for improving standards and industry capa-
bilities can be crafted. 
 The need to deconstruct standards 
 A respondent from Kenya on being asked what standards were, remarked 
as follows: ‘this is where we have a problem ... the word “standard” is 
misused both at global and national levels’. Such a remark underscores 
the need to deconstruct standards and classify them. He went on to 
describe what he considered to be standards, such as the guideline 
that describes good manufacturing practice (GMP) (which he termed a 
standard in itself), facility standards and personnel standards, as some 
of the key issues to be considered. In this section we discuss consecu-
tively the two types of standards identified above: technical standards 
and institutional or organizational-based standards 
 Technical and process standards 
 GMP guidelines are intended to be a set of minimum standards, covering 
recommendations on quality management, personnel, production 
facilities and equipment, documentation and records, production and 
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in-process controls, packaging and identification labelling, storage and 
distribution, laboratory controls, validation, complaints and recalls, and 
contract manufacturers (WHO, 2004). The diverse range of issues covered 
by GMP guidelines not only makes them a key and central lens for our 
discussion of pharmaceutical standards but also highlights why these 
guidelines are one of the most contested yet key drivers of the pharma-
ceutical industry. Under GMP we have chosen to focus on four standards 
that emerged as key in our research. Two of these standards (product 
and process) were classified as those which should not be compromised 
because of their direct relationship with patient and public health safety. 
The GMP process is critical for ensuring product quality, safety and effi-
cacy. As noted in Chapter 3, GMP standards constitute a ‘production 
culture’ interwoven with professional judgement as regulators decide on 
what is deemed adequate especially for processes and facility standards. 
 Product and process standards 
 There was consensus among the multinational and local pharmaceu-
tical manufacturers interviewed on the fact that product and process 
standards cannot be compromised. These they argued, should be the 
same wherever medicines are produced in the world. These standards 
are engineered in such a way that quality is built in and checked for at 
various stages and the evidence meticulously documented. The suppliers 
of raw materials have their facilities, processes and products vetted, and 
on receipt, raw materials are sampled and subjected to specific physical, 
chemical and biological tests. Raw materials are carefully stored ensuring 
avoidance of cross-contamination. There is a clear and documented chain 
of custody, traceability and accountability that is established along the 
whole process. In many African countries the production pharmacist 
is ultimately responsible and accountable for the release of batches of 
products after compliance with product and process standards as well as 
quality control tests. The quality control tests cover chemical, physical 
and biological characteristics of the product and avoiding contamina-
tion in the same three areas. Some of the tests, for example for tablets, 
include microbial tests, hardness and how well the tablet dissolves. 
 The drivers of product and quality standards are people, the produc-
tion equipment and laboratory equipment. Improving standards there-
fore requires in many instances equipment and skills upgrading. For 
example, a Zimbabwean firm improved ingredient drying in the wet 
granulation tablet-making process by investing in a high-capacity fluid 
bed dryer. They also invested in automatic capsule-filling machines 
to improve standards and productivity. On the question of whether 
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technical standards change there were diverse opinions in the inter-
views. Some respondents argued that technical standards do not change, 
whereas some regulators reported that technical standards have become 
more stringent with time. One interesting perspective came from a 
technical expert who when asked by researchers in Tanzania whether 
very stringent GMP is necessary, argued that for infusions and injecta-
bles (parenterals), it was essential that they have to be sterile because 
they go straight into the bloodstream. However, he said, for tablets, 
the minimum safe requirements are different because they go into the 
stomach. Yet, he argued, current requirements are that they should be 
‘almost sterile’, a standard hard to attain for manufacturers in Tanzania, 
and more stringent than essential good hygienic standards using good 
SOPs (standard operating procedures). 
 It is insights or perspectives such as these that need to be debated by 
those responsible for designing the road maps for upgrading standards 
in all their forms for the pharmaceutical sector. Our discussion, however, 
does not delve into the technicalities of GMP and the specific tests and 
indicators of quality. Our intention is to spark debate. In separate conver-
sations, UK compliance experts acknowledge that there are different 
interpretations of GMP. What the US FDA means by GMP compliant is 
not necessarily what Europe’s EMA means by GMP compliant and by 
extension what different African countries mean by GMP compliance. 
This argument resonates with the standards of the regulators as referred 
to by a Kenyan technical expert. It therefore becomes difficult according 
to the Kenyan expert to bring into one country a product produced in 
another, hence the African regulatory harmonization efforts described 
later in this chapter. 
 Facility and personnel standards 
 Another set of standards that technical experts in Kenya identified are 
facility and personnel standards. These encompass environmental and 
structural standards for buildings and health, educational and tech-
nical standards for personnel (which are often assumed). One Kenyan 
respondent remarked that ‘[facility standards] – that’s where the problem 
of Africa lies’. He reported that facility standards are assumed but not 
clearly enunciated by regulators, and are especially problematic for old 
production facilities that have to be refurbished. A Kenyan respondent 
said, for example, that the WHO talks of ‘competent people and suitable 
premises’ in its requirements for pre-qualification – which, however, 
leaves a lot of room for different interpretations. Facility standards 
are linked to environmental standards and determine air quality and 
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freedom from contamination through physical separation. Personnel 
standards include technical know-how, hygiene standards (medical 
check-ups included) and administrative skills as discussed later. Thus 
personnel standards cover diverse skills sets depending on functions, 
which might include but are not limited to analytical and organic 
chemistry, microbiology, plant engineering, production, pharmacovig-
ilance, quality assurance and research and development. Facility and 
personnel standards formed the class of standards for which improve-
ment, according to the technical experts we interviewed, should be 
approached in a gradual and cumulative manner. In Tanzania, regula-
tors reported that they know that the firms are growing and they give 
them ‘timelines’ for improvement. These are the classes of standards 
that we classify as being mutable. 
 Organizational/institutional aspects of standards 
 The supply of medicines and other medical products into the health 
delivery systems is intensively regulated and governed by strict product, 
process, marketing and institutional standards. The need for regulation 
comes from information asymmetry between the producers on one side 
and patients and clinicians on the other side. Patients cannot assess 
safety or observe quality and efficacy of medicines on their own, and 
neither can the medical practitioners who decide on their behalf (Harper, 
2007). This is where regulatory bodies come in, by seeking evidence of 
compliance with guidelines, rules and regulations to give credibility and 
legitimacy to organizations inspected. Accreditation and certification 
are an institutionally based regime of standards that are built on and 
meant to validate the technical, process, facility and personnel stand-
ards as reflected in the various guidelines such as GLP, GCP, GMP, Good 
Distribution Practice and pharmacovigilance. 
 The challenge for Africa rests in skills shortages at the regulator and 
among compliance managers at firms. As the firm operates, it records 
data which must be managed and produced as evidence to the regulators 
(inspectors). This process requires someone with a technical background 
who also is conversant with data management and documentation. The 
regulators in addition to the physical inspections also analyse docu-
ments and check against the set norms. As discussed earlier, this is where 
the judgement of the assessor (regulator) comes into play. These stand-
ards are of an organizational and institutional nature and are dominated 
by soft issues of training and retaining human capital. 
 These institutional/organizational standards tend to be resource-
driven and path dependent. Their evolution depends in part on historical 
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legacies of national institutions, industrial capabilities and tertiary 
training that included practice-based polytechnic training. South Africa 
and Zimbabwe as a result have relatively well-developed medicines regu-
latory systems. For South Africa the main piece of legislation shaping 
pharmaceutical standards is the Medicines and Related Substances 
Control Act (1965) and its various amendments. The Medicines Control 
Council (MCC), a public sector body tasked with regulating pharmaceu-
tical products in South Africa has eleven expert committees, which eval-
uate the safety and efficacy of a drug submitted for approval and they 
inform the decisions of the MCC. Apart from the Registrar of Medicines, 
all members of the MCC committees are engaged on a part-time basis, 
including the evaluators, who are often in full-time employment else-
where. There is, however, concern on such a heavy reliance on external 
expertise. 
 The Medicines Control Council (MCC) comprises four units, inspec-
torate and law enforcement, operations and administration, clinical 
and medicines registration. These units perform an administrative and 
coordinating role, facilitating the work of the expert committees. The 
MCC works within, and is influenced by, the public sector institutional 
context, as well as serving as the local competent authority for moni-
toring implementation of requirements from agencies such as the WHO, 
FDA and ICH in pharmaceutical manufacturers operating in South 
Africa. In terms of skills, respondents in South Africa also identified loss 
of regulatory skills especially at regulatory bodies as a key challenge. 
They reported that it took a long time to train a competent regulatory 
person, especially those with industrial experience, and as a result they 
are perpetually in training mode. The firms also reported that they face 
the same skills training and retention problems. 
 Harmonization to upgrade regulatory standards 
 An interesting issue identified by experts in the Kenyan pharmaceutical 
industry was the issue of the ‘standard’ of the regulatory bodies them-
selves. Different countries have different regulatory capacities and capa-
bilities. Highly resource-limited countries do not have the same capacity 
and capabilities as resource-rich countries. As a result, manufacturers fear 
that accreditation by one country does not equate to the same level of 
stringency as accreditation by another. Interviewees reported that some 
countries in the East African region had few regulatory pharmacists who 
looked at dossiers and at the same time had to do factory inspections – 
an impossible task. 
 These realities are some of the catalysts for regional medicines 
harmonization initiatives such as the African Medicines Regulatory 
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Harmonisation (AMRH) initiative led by the New Partnership for 
Africa’s Development (NEPAD). In recognition of regulatory capacity 
limitations for some countries and its consequent socio-economic 
impact, NEPAD Agency undertook, in collaboration with partners 2 
to initiate the African Medicines Regulatory Harmonization (AMRH) 
Programme since 2009. The AMRH initiative is part and parcel of the 
implementation of the African Union Pharmaceutical Manufacturing 
Plan for Africa (PMPA) (see Chapter 15) and aims to facilitate access to 
quality, safe and efficacious medicines to the African people by working 
through the existing political structures, and the regional economic 
communities (RECs). 
 In particular, the initiative aims to catalyse the establishment of effec-
tive national, regional and continental medicines regulatory agencies, 
and has made significant progress since 2009 in Eastern, Western and 
Southern Africa towards transparent, efficient and effective regulatory 
systems that provide assurance of faster approval of medical products and 
technologies that meet internationally acceptable standards of quality, 
safety and efficacy. Some of the key aspects focussed on are harmonized 
guidelines for registration of medicines, good manufacturing practice 
(GMP) inspection guidelines, quality management systems (QMS) and 
information management system (IMS). 
 Through NEPAD Agency’s coordination, the East African Community 
(EAC) successfully launched the Medicines Regulatory Harmonization 
(MRH) programme in March 2012, and is now at implementation stage 
with substantial progress made in the endorsement of the harmonized 
guidelines for registration of medicines, good manufacturing practice 
(GMP) inspection guidelines, quality management systems (QMS) and 
information management systems (IMS). The NEPAD Agency has under-
taken to expand the AMRH programme to other RECs beginning with 
the Economic Community of West African States (ECOWAS) through its 
health agency, the West African Health Agency (WAHO) in collabora-
tion with the West African Economic and Monetary Union (UEMOA). 
The MRH Programme for West Africa was launched on 2 February 2015. 
Progress has also been made on implementation of the programme in 
the Southern African Development Community and central African 
regions. 
 Cost implications of standards 
 Regulation raises numerous questions concerning compliance costs in 
relation to benefits obtained, transaction costs associated with regula-
tory administration and enforcement, and unanticipated or unwanted 
responses on the part of the regulated industry. Regulations may have 
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high individual compliance costs, which are compounded by the fact 
that organizations are simultaneously attempting to comply with other, 
possibly conflicting regulations. When regulatory standards or mecha-
nisms conflict, they may prevent one another from achieving their 
intended benefit. Increasing legislative controls in highly complex, 
and heavily regulated arenas such as health care can lead to ‘regula-
tory inflation’ rather than enhanced compliance. Moreover, the risks of 
compliance failures and regulatory inflation are heightened in the field 
of healthcare because jurisdiction is often fragmented and operates at 
multiple layers from global to local levels (Mugwagwa et al., 2015). 
 The consensus from South African respondents with respect to stand-
ards was that innovation, technological capability upgrading and health 
delivery were cost-sensitive processes, and that while adopting and 
keeping standards came at a cost, higher costs were being incurred from 
policy and regulatory uncertainties on the one hand and inefficient 
quality assurance systems on the other. Trying to curb costs today by 
compromising on standards would lead to ‘fewer drugs to treat current 
and future generations’, but taming the policy and regulatory jungle to 
ensure cost-effective and sustainable compliance with standards would 
be good for companies, regulators and patients in the short and long 
runs. Multiple accreditation has direct bottom-line impact. 
 The Kenyan standards and upgrading road map 
 Respondents in Kenya were in general agreement that product and 
process standards are necessary and that they should be seen as ‘minimum 
regulatory expectations’ required to manufacture a product that meets 
specific needs, that is, fits the purpose for which it is made. Kenya has 
developed a road map for upgrading standards. They acknowledge that it 
is a gradual process requiring multi-sectoral coordination and concerted 
efforts. In an interview, an industry expert involved in designing and 
developing the road map for the country said:
 So we came up and said you must solve the problem, but it’s not a 
small one ... we looked at the whole scenario and came up with seven 
key areas 
 which are detailed below as direct quotes:
 1.  You must have a road map for the local industry to improve because 
you cannot shut down any one of them because they have been 
producing. 
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 2.  You must have a system where you check the quality of the product 
on the market and remove the ones which are not performing and 
remain with those which are performing well. 
 3.  You must have someone overseeing the market and industry and 
that is the regulator, you must incentivize the capacity and improve 
its capacity. 
 4.  Whereas the industry is trying to achieve the standards, it’s going 
to cost money, so you should look for a way where they can get the 
money. 
 5.  You must provide the incentives for the time the industry is 
improving, they must not improve and lose their market, so you 
must protect it and come up with incentives that will help them. 
 6.  You must come up with a strategy for capacity building of human 
[skills], their capacity to undertake this both in the regulatory and in 
the private sector 
 7.  There are those items which are essential for the industry to place 
their products on the market, but not one single company can do 
it alone, so you must put them together and see how they can be 
shared, and this is what you call the support services or shared 
platform. 
 Recognizing that they could not do all seven activities at once, they 
prioritized the first initiative. They developed the road map, and by 
mid-2014 the technical aspect had been completed and they were waiting 
for the narrative part of the document, endorsements and final launch. 
A concerted effort to involve industry, regulators and the Ministry of 
Industrialization was made during the process of developing the road 
map (Technical Expert, Kenya, 2014). The technical expert through his 
networks brought together the ministers for health and industrialization 
in a joint meeting to discuss the road map. 
 Money for upgrading processes and standards 
 Kenya realized that the process of upgrading production facilities and 
machinery would impose financing constraints on affected firms. The 
fourth point in the strategy above deals with the need to facilitate funds 
availability. To that end they engaged the Kenyan Bankers Association, 
who informed them of their fears about funding pharmaceuticals 
production. According to the pharmaceutical industry respondent, the 
bankers said: ‘We are risk-based institutions, we go only where there 
is less risk, but in pharmaceuticals the risks are so high that we dare 
not’. This statement points to issues of finance capability on the part of 
banks (see Chapter 15). Reinforcing the challenge of finance capability, 
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one respondent cited an example of a Development Bank which refused 
to fund a quality control laboratory because they said they could not 
demonstrate what would come out of the laboratory. The pharmaceu-
tical technical expert argued that the bank failed to see the overall picture 
and how the quality control laboratory would result in better produc-
tion processes and products. The bankers themselves acknowledged that 
they lack a deep appreciation of the industry dynamics:
 We have never got an expert who we can trust to go there [pharma-
ceutical industry] and do an evaluation; and I said to them then I 
should become a banker. (Technical expert, Kenyan pharmaceutical 
sector, 2014) 
 Efforts are under way to bring industrialists and bankers together to try 
and bridge the gap in knowledge about the sector and hence improve 
risk analysis. Kenya’s road map, however, evidences a purposive and 
integrated approach to improving standards and upgrading facilities. 
In interviews the technical experts acknowledged that this would be a 
long process the success of which depends on availability of resources 
for investment in equipment and people. The programme in Kenya is 
being supported by UNIDO, supplementing limited national resources 
allocated to this important initiative. Kenya appears to be taking control 
of the issue of standards, and although they are still at the initial steps 
of implementing the programme, there are lessons that other African 
technical and policy people can learn. 
 Initiatives focusing on building capacity and capabilities on standards 
in local manufactures require coherence/harmony between different 
approaches. Some global institutions working with African countries, 
such as the WHO, take a product-by-product approach to standards 
(WHO pre-qualification), whereas UNIDO and GIZ take a systemic 
technological approach. This helps to explain different approaches to 
improving standards in African countries. UNIDO and GIZ prefer to 
build local technical skills by training local industry. In the next section 
we look at the Indian standards upgrading to extract lessons that Africa 
can use. 
 What lessons can Africa learn from the Indian GMP 
upgrading road map? 
 Over the last three decades the Indian pharmaceutical industry has 
emerged as a major supplier of cheap generic drugs across the world. 
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The Indian government was credited for infusing life into the Indian 
pharmaceutical industry through industrial and regulatory policy inter-
vention, and the success of the Indian firms made these interventions 
a recipe for pharmaceutical industrial development in other emerging 
countries (see also Chapter 10). 
 Pharmaceutical production in India is governed by the Drugs and 
Cosmetic Act of 1940 and the much amended Drug and Cosmetics Rules of 
1945. The Act and Rules regulate drugs imported, manufactured, distrib-
uted and sold. No pharmaceutical products can be imported, manufac-
tured, stocked, distributed or sold unless they meet the quality standards 
laid down in the Act. An Indian Pharmacopoeia was published in 1955, 
and over the years problems in controlling spurious or counterfeit medi-
cines have dominated Indian policy agendas. The Indian government 
initially aimed to enforce GMP standards in all pharmaceutical manu-
facturing firms via the Drug Policy of 1986. This laid down requirements 
for GMP adherence in Schedule M of the Rules, which came into force in 
1987. Schedule M was strengthened to require WHO-GMP standards, by 
amendment in 2001, with the aims of ensuring that firms upgraded and 
of eradicating counterfeit and substandard drugs. Those pharmaceutical 
firms that did not comply with these regulations have been refused 
manufacturing licenses from each State Drug Control Administration 
office. In the case of manufacturing plants approved before December 
2001, non-compliance led to their licenses being revoked, forcing closure 
of these manufacturing facilities. 
 The financial cost involved in complying with GMP has proved a 
significant barrier for small companies in India to upgrade manufac-
turing facilities. Upgrading of manufacturing plants by small scale 
firms would result in those firms graduating to become medium-scale 
firms, thereby losing the tax benefits and other concessions available to 
small scale enterprises. The Indian government responded to this issue 
by providing some concessions for the Indian firms, increasing invest-
ment limits and turnover thresholds for eligibility as a small-scale firm. 
On the other hand, several large-scale companies upgraded their plants 
to access high-income country markets, and their significant financial 
resources made this transition feasible. The deadline for implementation 
of GMP was postponed from 31 December 2003 to 31 December 2004, 
and then postponed again until 30 June 2005. Each State Drug Control 
Administration office also had the authority to extend the deadline of 
compliance within its area of jurisdiction. 
 In spite of these concessions, this mandatory application of GMP had 
a significant impact on the Indian pharmaceutical firms. According to 
240 Banda, Mugwagwa, Kale and Ndomondo-Sigonda
official estimates, in 2001, 327 pharmaceutical manufacturing plants 
closed, had their licenses suspended, or were forced to shift to some other 
state. A total of 370 plants were not in a position to comply with GMP 
and have closed since 2005 (Planning Commission, 2002, par. 7.1.192). 
In addition to an increase in competitive pressure, GMP compliance has 
been another force that has induced the exit of small firms from the 
market. However, the introduction of GMP has also contributed to the 
enhancement of trust in Indian products in the global market. In addi-
tion, complying with GMP standards of the US and Europe has increased 
exports to Western countries and expanded the opportunity for contract 
manufacturing. 
 Since 2000, the strong presence of the Indian firms in the markets 
of advanced countries, and specifically in the US, has brought severe 
scrutiny from regulatory agencies around the world. More numerous 
FDA inspections led to an increase in the number of warning letters 
and import bans for the Indian firms (see also Chapter 6). The FDA has 
identified a number of Indian pharmaceutical manufacturers who have 
had problems with data integrity and GMP at their respective facilities. 
Gaffney (2015) notes that since GMP data are intended to ensure that 
products meet pre-established specifications, absence of credible data 
management creates concern that these products cannot be trusted. 
 The case of Ranbaxy provides a prime example of the FDA atti-
tude towards implementation of GMP in the Indian firms. The FDA 
has repeatedly issued warning letters and import bans to two of the 
company’s manufacturing plants because of data integrity issues. The 
warning letters note that the FDA has concerns about non-compliance 
with US current Good Manufacturing Practices requirements, although 
‘FDA has no evidence of harm to any patients who have taken drugs 
made in these two facilities’ (Jeffrey et al., 2001; US Food and Drug 
Administration, 2008). Elaborating on their concerns at one of the 
manufacturing plants, the FDA warning letter focuses on concern that 
‘written records of major equipment cleaning and use are inaccurate’ 
(USFDA, 2008) and notes that their investigative team uncovered 14 
instances ‘where ... records for equipment used in manufacturing opera-
tions ... included initials or signatures of employees who reportedly veri-
fied cleaning of equipment but were not shown as present by security 
log records’ (USFDA, 2008). 
 Jeffrey (2001) argues that this experience highlights the way in which 
international regulatory authorities play a crucial and detailed role 
in setting production and data management standards at the Indian 
manufacturing sites, using the set of regulations and rules developed to 
Upgrading Pharmaceutical Standards in Africa 241
protect high-income countries’ consumers. The cost of implementing 
and complying with these regulations is incurred by the Indian manu-
facturers and government and in most cases passed on to the Indian 
consumers. Further, these regulatory troubles have caused the Indian 
firms significant revenue losses and reduced competition in generic 
markets, contributing to profit margins of multinational pharmaceu-
tical companies. This experience raises issues about the authority of 
developing country governments in setting standards, and about the 
appropriateness of international standards to the local context in the 
developing countries. 
 Concluding discussion 
 Pharmaceutical standards and regulations are necessary yet complex 
institutions which change over time, operate at various vertical and 
horizontal scales, are subject to different interpretations and applica-
tions and have potential to assist the manufacturing of, and access to, 
safe efficacious medicines. However, they can also act as undesirable 
market entry barriers. African pharmaceutical industry players accept 
that standards are important, but they contend that the other regions of 
the world which are more advanced now ‘did not themselves improve 
their standards overnight’. Rather, it was a gradual and long drawn-out 
process as countries learned best practice from the first movers. African 
technical experts argue that Africa should not be pressured to catch up 
‘overnight’. When African and other developing countries look broadly 
at pharmaceutical standards, they need to view them as a process, and 
there is therefore a need to introduce clear road maps for a gradual 
strengthening of the requirements for standards, driven by local or 
regional regulatory institutions. 
 We conclude that in order to improve standards and upgrade techno-
logical capabilities, first, standards need to be deconstructed and under-
stood based on risk management principles. Second, institutional or 
organizational standards that are based on judgement and can be grad-
ually improved should be recognized as mutable in that sense. Third, 
technically based standards should also be viewed from a risk manage-
ment perspective. Once this has been done, African technical and policy 
actors need to take control of the issue of pharmaceutical standards and 
to design and manage context-sensitive regulatory frameworks and road 
maps backed by an evidence base that draws from a clear understanding 
of standards, attendant risk profiles and their role in industry develop-
ment and access to medicines. 
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